Janus-faced role of SIRT1 in tumorigenesis

Annals of the New York Academy of Sciences

Volumn 1271, Issue 1, 2012, Pages 10-19

  Song, Na Young ^a   Surh, Young Joon ^a  

^a Seoul National University   (South Korea)

Author keywords

Cancer; SIRT1; Subcellular localization

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; LIPOPOLYSACCHARIDE; MULTIDRUG RESISTANCE PROTEIN 1; SIRTUIN 1; STAT3 PROTEIN; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL DEATH; CELL SURVIVAL; CELLULAR DISTRIBUTION; COLORECTAL CANCER; DNA REPAIR; GENOMIC INSTABILITY; HUMAN; LIVER CANCER; NONHUMAN; ONCOGENE C MYC; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR MICROENVIRONMENT;

EID: 84867380741     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06762.x     Document Type: Article

References (97)

1. Guarente, L. 2011. Franklin H. Epstein Lecture: sirtuins, aging, and medicine. N. Engl. J. Med. 364: 2235-2244.
2. Houtkooper, R.H., E. Pirinen & J. Auwerx. 2012. Sirtuins as regulators of metabolism and healthspan. Nat. Rev. Mol. Cell Biol. 13: 225-238.
3. Cohen, H.Y. et al. 2004. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305: 390-392.
4. Boily, G. et al. 2008. SirT1 regulates energy metabolism and response to caloric restriction in mice. PLoS One 3: e1759.
5. Borra, M.T., B.C. Smith & J.M. Denu. 2005. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 280: 17187-17195.
6. Baur, J.A. et al. 2006. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337-342.
7. Chen, D. & L. Guarente. 2007. SIR2: a potential target for calorie restriction mimetics. Trends Mol. Med. 13: 64-71.
8. Price, N.L. et al. 2012. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 15: 675-690.
9. Imai, S. et al. 2000. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403: 795-800.
10. Haigis, M.C. & D.A. Sinclair. 2010. Mammalian sirtuins: biological insights and disease relevance. Annu. Rev. Pathol. 5: 253-295.
11. Vaziri, H. et al. 2001. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107: 149-159.
12. Yang, X.J. & E. Seto. 2008. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol. Cell 31: 449-461.
13. Kim, E.J. et al. 2007. Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. Mol. Cell. 28: 277-290.
14. Kim, J.E., J. Chen & Z. Lou. 2008. DBC1 is a negative regulator of SIRT1. Nature 451: 583-586.
15. Yang, Y. et al. 2007. SIRT1 sumoylation regulates its deacetylase activity and cellular response to genotoxic stress. Nat. Cell Biol. 9: 1253-1262.
16. Sasaki, T. et al. 2008. Phosphorylation regulates SIRT1 function. PLoS One 3: e4020.
17. Nasrin, N. et al. 2009. JNK1 phosphorylates SIRT1 and promotes its enzymatic activity. PLoS One 4: e8414.
18. Luo, J. et al. 2001. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107: 137-148.
19. Jeong, J. et al. 2007. SIRT1 promotes DNA repair activity and deacetylation of Ku70. Exp. Mol. Med. 39: 8-13.
20. Li, X. et al. 2007. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol. Cell 28: 91-106.
21. Rodgers, J.T. et al. 2005. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434: 113-118.
22. Nemoto, S., M.M. Fergusson & T. Finkel. 2005. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}. J. Biol. Chem. 280: 16456-16460.
23. Kundu, J.K. & Y.J. Surh. 2012. Emerging avenues linking inflammation and cancer. Free Radic. Biol. Med. 52: 2013-2037.
24. Zhu, X. et al. 2011. Activation of Sirt1 by resveratrol inhibits TNF-alpha induced inflammation in fibroblasts. PLoS One 6: e27081.
25. Zhang, Z. et al. 2010. Roles of SIRT1 in the acute and restorative phases following induction of inflammation. J. Biol. Chem. 285: 41391-41401.
26. Yoshizaki, T. et al. 2010. SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. Am. J. Physiol. Endocrinol. Metab. 298: E419-E428.
27. Purushotham, A. et al. 2009. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 9: 327-338.
28. Xu, F. et al. 2010. Lack of SIRT1 (Mammalian Sirtuin 1) activity leads to liver steatosis in the SIRT1+/- mice: a role of lipid mobilization and inflammation. Endocrinology 151: 2504-2514.
29. Rajendrasozhan, S. et al. 2008. SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am. J. Respir Crit. Care Med. 177: 861-870.
30. Yeung, F. et al. 2004. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 23: 2369-2380.
31. Singh, U.P. et al. 2010. Resveratrol (trans-3, 5, 4'-trihydroxystilbene) induces silent mating type information regulation-1 and down-regulates nuclear transcription factor-kappaB activation to abrogate dextran sulfate sodium-induced colitis. J. Pharmacol. Exp. Ther. 332: 829-839.
32. Yu, H., D. Pardoll & R. Jove. 2009. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9: 798-809.
33. Nie, Y. et al. 2009. STAT3 inhibition of gluconeogenesis is downregulated by SirT1. Nat. Cell Biol. 11: 492-500.
34. Sestito, R. et al. 2011. STAT3-dependent effects of IL-22 in human keratinocytes are counterregulated by sirtuin 1 through a direct inhibition of STAT3 acetylation. FASEB J. 25: 916-927.
35. Gao, Z. & J. Ye. 2008. Inhibition of transcriptional activity of c-JUN by SIRT1. Biochem. Biophys. Res. Commun. 376: 793-796.
36. Rajamohan, S.B. et al. 2009. SIRT1 promotes cell survival under stress by deacetylation-dependent deactivation of poly(ADP-ribose) polymerase 1. Mol. Cell Biol. 29: 4116-4129.
37. Ming, M. et al. 2010. Regulation of global genome nucleotide excision repair by SIRT1 through xeroderma pigmentosum C. Proc. Natl. Acad. Sci. U. S. A. 107: 22623-22628.
38. Oberdoerffer, P. et al. 2008. SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell 135: 907-918.
39. Palacios, J.A. et al. 2010. SIRT1 contributes to telomere maintenance and augments global homologous recombination. J. Cell Biol. 191: 1299-1313.
40. Yuan, J., K. Minter-Dykhouse & Z. Lou. 2009. A c-Myc-SIRT1 feedback loop regulates cell growth and transformation. J. Cell Biol. 185: 203-211.
41. Kabra, N. et al. 2009. SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J. Biol. Chem. 284: 18210-18217.
42. Rusin, M., A. Zajkowicz & D. Butkiewicz. 2009. Resveratrol induces senescence-like growth inhibition of U-2 OS cells associated with the instability of telomeric DNA and upregulation of BRCA1. Mech. Ageing Dev. 130: 528-537.
43. Wang, R.H. et al. 2008. Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol. Cell 32: 11-20.
44. Powell, M.J. et al. 2011. Disruption of a Sirt1-dependent autophagy checkpoint in the prostate results in prostatic intraepithelial neoplasia lesion formation. Cancer Res. 71: 964-975.
45. Lim, J.H. et al. 2010. Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. Mol. Cell 38: 864-878.
46. Nakamaru, Y. et al. 2009. A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9. FASEB J. 23: 2810-2819.
47. Bourguignon, L.Y., W. Xia & G. Wong. 2009. Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells. J. Biol. Chem. 284: 2657-2671.
48. Wang, R.H. et al. 2008. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell. 14: 312-323.
49. Firestein, R. et al. 2008. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One 3: e2020.
50. Huffman, D.M. et al. 2007. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 67: 6612-6618.
51. Zhang, Y. et al. 2009. Deacetylation of cortactin by SIRT1 promotes cell migration. Oncogene 28: 445-460.
52. Chen, H.C. et al. 2012. SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis. Ann. Surg. Oncol. 19: 2011-2019.
53. Sung, J.Y. et al. 2010. Balance between SIRT1 and DBC1 expression is lost in breast cancer. Cancer Sci. 101: 1738-1744.
54. Feng, A.N. et al. 2011. Expression of SIRT1 in gastric cardiac cancer and its clinicopathologic significance. Int. J. Surg. Pathol 19: 743-750.
55. Zhao, G. et al. 2011. SIRT1 RNAi knockdown induces apoptosis and senescence, inhibits invasion and enhances chemosensitivity in pancreatic cancer cells. Gene Ther. 18: 920-928.
56. Stunkel, W. et al. 2007. Function of the SIRT1 protein deacetylase in cancer. Biotechnol. J. 2: 1360-1368.
57. Jang, S.H. et al. 2012. Loss of SIRT1 histone deacetylase expression associates with tumour progression in colorectal adenocarcinoma. J. Clin. Pathol. 65: 735-739.
58. Jang, K.Y. et al. 2008. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am. J. Surg. Pathol. 32: 1523-1531.
59. Jang, K.Y. et al. 2009. Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology. 41: 366-371.
60. Cha, E.J. et al. 2009. Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin. Cancer Res. 15: 4453-4459.
61. Chang, T.C. et al. 2007. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell 26: 745-752.
62. Yi, J. & J. Luo. 2010. SIRT1 and p53, effect on cancer, senescence and beyond. Biochim. Biophys. Acta. 1804: 1684-1689.
63. Chen, W.Y. et al. 2005. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 123: 437-448.
64. Wong, S. & J.D. Weber. 2007. Deacetylation of the retinoblastoma tumour suppressor protein by SIRT1. Biochem J. 407: 451-460.
65. Ikenoue, T. et al. 2008. PTEN acetylation modulates its interaction with PDZ domain. Cancer Res. 68: 6908-6912.
66. Marcu, K.B., S.A. Bossone & A.J. Patel. 1992. Myc function and regulation. Ann. Rev. Biochem. 61: 809-860.
67. Menssen, A. et al. 2012. The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc. Natl. Acad. Sci. USA 109: E187-196.
68. Mao, B. et al. 2011. Sirt1 deacetylates c-Myc and promotes c-Myc/Max association. Int. J. Biochem. Cell Biol. 43: 1573-1581.
69. Marshall, G.M. et al. 2011. SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability. PLoS Genet. 7: e1002135.
70. Yuan, H. et al. 2012. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood 119: 1904-1914.
71. Sundaresan, N.R. et al. 2011. The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Sci. Signal. 4: ra46.
72. Ota, H. et al. 2006. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene. 25: 176-185.
73. Li, L. et al. 2012. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 21: 266-281.
74. Kojima, K. et al. 2008. A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem. Biophys. Res. Commun. 373: 423-428.
75. Lara, E. et al. 2009. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene. 28: 781-791.
76. Peck, B. et al. 2010. SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol. Cancer Ther. 9: 844-855.
77. Chen, J. et al. 2011. Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth. Cancer Res. 71: 4138-4149.
78. Ford, J., M. Jiang & J. Milner. 2005. Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res. 65: 10457-10463.
79. Geiger, T.R. & D.S. Peeper. 2009. Metastasis mechanisms. Biochim. Biophys. Acta. 1796: 293-308.
80. Eades, G. et al. 2011. miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. J. Biol. Chem. 286: 25992-26002.
81. Byles, V. et al. 2012. SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene. Jan 16. doi:10.1038/onc.2011.612. [Epub ahead of print].
82. Holloway, K.R. et al. 2010. SIRT1 regulates Dishevelled proteins and promotes transient and constitutive Wnt signaling. Proc. Natl. Acad. Sci. U. S. A. 107: 9216-9221.
83. Chu, F. et al. 2005. Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1. Cancer Res. 65: 10183-10187.
84. Liang, X.J. et al. 2008. SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism. Mol. Cancer Res. 6: 1499-1506.
85. Oh, W.K. et al. 2010. Amurensin G, a potent natural SIRT1 inhibitor, rescues doxorubicin responsiveness via down-regulation of multidrug resistance 1. Mol. Pharmacol. 78: 855-864.
86. Wang, Z. et al. 2012. SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells. Oncogene. Mar 12. doi:10.1038/onc.2012.83. [Epub ahead of print].
87. Sun, Y. et al. 2007. Downregulation of Sirt1 by antisense oligonucleotides induces apoptosis and enhances radiation sensitization in A549 lung cancer cells. Lung Cancer 58: 21-29.
88. Tanno, M. et al. 2007. Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1. J. Biol. Chem. 282: 6823-6832.
89. Moynihan, K.A. et al. 2005. Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. Cell Metab. 2: 105-117.
90. Zhang, J. 2007. The direct involvement of SirT1 in insulin-induced insulin receptor substrate-2 tyrosine phosphorylation. J. Biol. Chem. 282: 34356-34364.
91. Byles, V. et al. 2010. Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K/IGF-1R signaling in human cancer cells. Int. J. Biol. Sci. 6: 599-612.
92. Calcagno, D.Q. et al. 2009. MYC insertions in diffuse-type gastric adenocarcinoma. Anticancer Res. 29: 2479-2483.
93. O'Brate, A. & P. Giannakakou. 2003. The importance of p53 location: nuclear or cytoplasmic zip code Drug Resist. Updat. 6: 313-322.
94. Green, D.R. & G. Kroemer. 2009. Cytoplasmic functions of the tumour suppressor p53. Nature 458: 1127-1130.
95. Schug, T.T. & X. Li. 2011. Sirtuin 1 in lipid metabolism and obesity. Ann. Med. 43: 198-211.
96. Orecchia, A. et al. 2011. Sirtinol treatment reduces inflammation in human dermal microvascular endothelial cells. PLoS One 6: e24307.
97. Sugino, T. et al. 2010. Protein deacetylase SIRT1 in the cytoplasm promotes nerve growth factor-induced neurite outgrowth in PC12 cells. FEBS Lett. 584: 2821-2826.